Author
Stephen Page
Writer on DMT, ayahuasca, iboga and tryptamine research. LLB; incoming MSc in Psychedelics: Mind, Medicine and Culture, University of Exeter (2026)
ARDMT Field Notes
DMT for Parkinson's: Sigma-1 Neuroprotection in a 6-OHDA Model
Calleja-Conde and Morales-García extend the Madrid group's DMT–sigma-1 neuroprotection case into a Parkinson's model. Suggestive, not yet definitive — but building.
ARDMT Field Notes
DMT shows neuroprotective effects in a Parkinson's rat model — a Madrid group extends its σ1R hypothesis
Could DMT protect dopamine neurons? A new preclinical study from Madrid says yes — at least in rats. Here's what the data show, what the σ1R–NRF2 mechanism implies, and why translation to human Parkinson's remains an open question.
ARDMT Field Notes
Ayahuasca Alkaloids in Hair: A New Long-Window Exposure Biomarker
Santos et al. validate a hair-analysis method for DMT and β-carbolines — turning a single strand into a months-long record of ayahuasca exposure.
Cabinet of Marginalia
The Committee on Extraordinary Claims. Part 1
The margin is where the medieval scribe drew dragons and pulled faces while the main text held forth on theology. This is that margin.
ARDMT Field Notes
Szára's 1956 self-experiment: the Budapest dose that launched DMT research
Cold War Hungary, 1956: Stephen Szára couldn't get LSD, so he made DMT and dosed himself. Modern psychedelic research began that afternoon.
Understanding
Endogenous DMT in Humans: A Critical Review of the State of the Evidence
A critical review of the evidence, the inferences drawn from it, and the limits of cross-species extrapolation: detection, biosynthesis, function and psychoactive sufficiency .
Exploration
DEEP DIVE #1 Five Hundred Million Years Apart, Touching Through the Glass: The Octopus, MDMA, and the Deep Chemistry of Social Connection
In 2018, Eric Edsinger and Gül Dölen published a short paper in Current Biology that posed an apparently absurd question: what happens when you give MDMA to an octopus?
ARDMT Field Notes
Can Halogenated DMT Analogues Be Non-Hallucinogenic? G-Protein Bias
A preprint shows 2-chloro and 2-bromo DMT analogues display G-protein bias at 5-HT2A — relevant to the hunt for non-hallucinogenic psychedelics.
ARDMT Field Notes
Long-Term Ayahuasca: Personality Shifts, Cognition Intact (Bouso)
Bouso compares chronic ayahuasca users with cannabis users and non-users: personality differs across groups, cognitive function is spared.
ARDMT Field Notes
Ayahuasca vs Meditation: Two Routes to Ego Dissolution?
Arqueros et al. compare hypo-egoic features in ayahuasca users and long-term meditators — testing whether pharmacology and contemplation reach the same place.
ARDMT Field Notes
2-Halogenated Tryptamines: How One Atom Reshapes DMT Pharmacology
Von Salm, McCorvy and Baumann profile 2-halogenated tryptamines: halogen choice at the 2-position reshapes 5-HT receptor selectivity and signalling bias.
ARDMT Field Notes
UCL's UNITy Trial: Can DMT Disrupt Alcohol Memory Reconsolidation?
UCL's UNITy trial pairs IV DMT with alcohol memory reactivation in heavy drinkers — testing whether DMT plasticity can rewrite addiction memories.